

July 21, 2021



Wake Network, Inc. and the Lieber Institute for Brain Development Announce Research Collaboration



Combining psychedelics research with the largest database of genetics for mental illness to innovate personalized medicine and safety.

TORONTO, July 21, 2021 /CNW/ - Wake Network, Inc. ("Wake" or the "Company"), a global leader in psilocybin mushroom research, production and the developer of genomics-based integration therapies, is pleased to announce a collaboration with the Lieber Institute for Brain Development (the "Lieber Institute"), a non-profit research Institution and an international leader in translating genetics into brain function, to develop a one-of-a-kind, genetics-based approach to psychedelic integration and clinical research on traumatic brain injury.

In the "Wake Genomics Project", Wake and the Lieber Institute aim to co-develop a genetics-based safety screening system to ensure the most effective therapies for patients through a combination of genome mapping, machine learning, and metabolic measurement. The project is one of the most robust genetics research initiatives in the emerging psychedelics space to date.

The Lieber Institute scientists examine the role of genetics and environment in brain development and function to better understand disorders such as schizophrenia, depression, traumatic brain injury and autism. The Lieber Institute houses the largest database of genetically profiled human brains in the world. The Institute is an independent non-profit located adjacent to the Johns Hopkins Medical Campus.

"What we are seeing is a seismic shift in demand to explore psychedelic therapies. The most important area of focus for this emerging industry in order to be successful is risk mitigation at both the compound level, but also at the psychiatric level," says Warren Needler, President of Wake. "These compounds can cause profound shifts in consciousness, and certainly sometimes with adverse results. The work that Wake and the Lieber Institute are pursuing addresses this and allows for the industry to advance safely."

The Wake Genomics Project officially kicks off this month and is a critical component to all clinical research underway at Wake.

"Traumatic brain injury is a devastating condition with limited treatment options," says Daniel R. Weinberger, M.D., Lieber Institute CEO & Director. "Personalized medicine that tailors treatment to a patient's unique genetics is a promising technique for the treatment of brain injury and other psychiatric disorders. We're excited to use the Lieber Institute's cutting-edge genetics in brain technology to help Wake ensure its research in this area is as safe and low risk as possible."

<https://www.newswire.ca/news-releases/wake-network-inc-and-the-lieber-institute-for-brain-development-announce-research-collaboration-898099953.html>

July 21,2021